Engineers Gate Manager’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-22,269
| Closed | -$35.4K | – | 2319 |
|
|
2024
Q1 | $35.4K | Hold |
22,269
| – | – | ﹤0.01% | 1821 |
|
|
2023
Q4 | $19.1K | Buy |
22,269
+11,240
| +102% | +$9.87K | ﹤0.01% | 1908 |
|
|
2023
Q3 | $11.8K | Buy |
+11,029
| New | +$22.8K | ﹤0.01% | 1724 |
|
|
2022
Q3 | – | Sell |
-27,026
| Closed | -$346K | – | 2177 |
|
|
2022
Q2 | $346K | Sell |
27,026
-13,587
| -33% | -$188K | 0.01% | 1320 |
|
|
2022
Q1 | $619K | Sell |
40,613
-1,597
| -4% | -$24.9K | 0.02% | 945 |
|
|
2021
Q4 | $748K | Buy |
42,210
+12,751
| +43% | +$245K | 0.03% | 778 |
|
|
2021
Q3 | $619K | Sell |
29,459
-29,721
| -50% | -$654K | 0.04% | 754 |
|
|
2021
Q2 | $1.17M | Buy |
59,180
+35,727
| +152% | +$836K | 0.08% | 365 |
|
|
2021
Q1 | $682K | Sell |
23,453
-10,278
| -30% | -$288K | 0.03% | 807 |
|
|
2020
Q4 | $1.02M | Sell |
33,731
-10,561
| -24% | -$231K | 0.04% | 589 |
|
|
2020
Q3 | $705K | Sell |
44,292
-13,214
| -23% | -$241K | 0.03% | 808 |
|
|
2020
Q2 | $1.14M | Buy |
57,506
+13,353
| +30% | +$255K | 0.06% | 546 |
|
|
2020
Q1 | $544K | Buy |
+44,153
| New | +$721K | 0.04% | 721 |
|
Engineers Gate Manager's NGM Position: Q2 2024 in Review
Engineers Gate Manager sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 22,269 shares — an estimated $35.4K sold.
Engineers Gate Manager first reported a position in NGM in Q1 2020 and held it in 13 quarters. The position peaked at $1.17M in Q2 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Engineers Gate Manager reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Engineers Gate Manager sold 22,269 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $35.4K.
- Engineers Gate Manager first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 13 quarters.
- Engineers Gate Manager's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.17M in Q2 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Engineers Gate Manager's 13F filing for Q2 2024, filed 14 Aug 2024.